5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital

4. Cue Biopharma, Inc. (NASDAQ:CUE)

Prosight Capital Stake Value: $7.3 million

Percentage of Prosight Capital’s 13F Portfolio: 4.59%

No. of Hedge Fund Holders: 15

Ranked fourth on the list of 10 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital is Cue Biopharma, Inc. (NASDAQ:CUE). It is headquartered in Massachusetts, United States. This clinical-stage biopharmaceutical firm is developing a new class of injectable biologics that precisely engage and control targeted T cells within the body to treat cancer and autoimmune diseases. Hawkins’ Prosight Capital increased stake in Cue Biopharma, Inc. (NASDAQ:CUE) by 14% during the second quarter of 2021 compared to the first quarter.

In the second quarter of 2021, Cue Biopharma, Inc. (NASDAQ:CUE) reported an EPS of -$0.33, beating estimates by $0.05. The company’s revenue in the second quarter came in at $2.73 million, an increase of 152.8 % year over year, and beat revenue estimates by $1.69 million.

At the end of the second quarter of 2021, 15 hedge funds in the database of Insider Monkey held stakes worth $101.3 million in Cue Biopharma, Inc. (NASDAQ:CUE), up from 14 the preceding quarter worth $106.5 million.